World Pharmaceutical Frontiers

World Pharmaceutical Frontiers serves as the top resource for leading pharmaceutical firms, offering trustworthy and precise insights into new trends and innovative technologies. This valuable information aids companies in making important business choices.

International

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#3377046

United States

#2075493

Health/Biotechnology and Pharmaceuticals

#1875

Traffic sources

Monthly visitors

Articles

Regeneron partners with Telesis Bio for swift on-site gene synthesis

1 week ago | worldpharmaceuticals.net | Swagath Bandhakavi

Telesis Bio has entered into a licensing agreement with Regeneron Pharmaceuticals to integrate its Gibson SOLA platform within the latter’s research and development (R&D) facilities. This deal allows Regeneron to utilise Telesis Bio’s automated platform for on-demand, high-throughput DNA and gene synthesis. The Gibson SOLA platform is a reagent-based system featuring a suite of software tools that can be integrated at various scales and throughput levels.
Alvotech, Advanz Pharma expand biosimilar partnership in Europe

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Alvotech and Advanz Pharma have expanded their strategic partnership to include three additional biosimilar candidates for the European market. The agreement builds on their existing partnership, which focuses on enhancing their biosimilar portfolio in Europe. The expanded collaboration covers biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab), and an undisclosed early-stage candidate.
Alcon receives FDA approval for Tryptyr to treat dry eye disease

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Alcon has secured approval from the US Food and Drug Administration (FDA) for Tryptyr (acoltremon ophthalmic solution) 0.003% to treat symptoms of Dry Eye Disease (DED). Tryptyr is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production, providing a new option for patients suffering from the multifactorial condition. The FDA approval is based on two Phase 3 trials, COMET-2 and COMET-3, involving over 930 patients with a history of DED.
Teva and Biolojic launch IND studies for BD9 in atopic dermatitis and asthma

1 week ago | worldpharmaceuticals.net | Swagath Bandhakavi

Teva Pharmaceutical Industries, in partnership with Biolojic Design, has initiated investigational new drug (IND)-enabling studies for BD9, a multibody designed to target both TSLP and IL-13. This development is part of Teva’s strategy to explore new treatments for TH2-driven inflammatory conditions, including atopic dermatitis and asthma.
Lilly to acquire SiteOne Therapeutics to expand pain pipeline

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Eli Lilly Company (Lilly) has agreed to acquire SiteOne Therapeutics, a biotechnology company specialising in small molecule inhibitors for pain treatment. The acquisition will expand Lilly’s pain management pipeline, featuring STC-004, a Phase 2 ready Nav1.8 inhibitor, which may offer a non-opioid solution for chronic pain patients.
Biogen and City Therapeutics partner to advance RNAi therapies

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Biogen and City Therapeutics have entered a strategic collaboration to develop novel RNA interference (RNAi)-based therapies targeting central nervous system diseases. The collaboration combines City Therapeutics’ next-generation RNAi engineering technologies with Biogen’s drug development expertiseUnder the partnership, City Therapeutics will receive a total of $46m, comprising a $16m upfront payment and a $30m investment for a convertible note representing a minority equity interest.
Shanghai Henlius Biotech gets EU orphan drug status for HLX22

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Shanghai Henlius Biotech has secured Orphan Drug Designation (ODD) from the European Commission for HLX22, its anti-HER2 monoclonal antibody to treat gastric cancer. The designation confirms the therapeutic potential of HLX22, which has also received ODD from the US Food and Drug Administration (FDA). HLX22 becomes the first anti-HER2-targeted therapy to achieve this status in both regions. The drug is currently being studied in the Phase 3 HLX22-GC-301 clinical study.
Lupin taps SteinCares to supply ranibizumab in Latin America

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

India-based pharmaceutical firm Lupin has signed a licensing agreement with SteinCares to supply Lupin’s biosimilar ranibizumab in Latin America, except in Mexico and Argentina. Under the agreement, SteinCares will be responsible for regulatory filings, registrations, and marketing of the biosimilar in the region, while Lupin will manage the manufacturing process.
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

1 week ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of Hepatocellular Carcinoma (HCC).
FUJIFILM Diosynth secures $3bn manufacturing deal with Regeneron

1 week ago | worldpharmaceuticals.net | Swagath Bandhakavi

FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organisation (CDMO), and US-based biotechnology company Regeneron Pharmaceuticals have formalised a decade-long manufacturing partnership valued at over $3bn. This agreement focuses on the production of biologic medicines within the US, directly impacting millions of patients globally.